Boehringer to Pay $13.5 Million Settlement for Improper Off-Label Promotion

Drug Industry Daily
A A
Boehringer Ingelheim agreed to pay $13.5 million to all 50 states and the District of Columbia to settle a lawsuit alleging the company promoted unapproved uses of prescription drugs and engaged in deceptive marketing.

To View This Article:

Login

Subscribe To Drug Industry Daily